focus -WSS

focus

author：knowledge 2025-10-03 00:38:58 - browse：32

The Food and Drug Administration is poised to tell drug and medical device makers how to better include people of color in the clinical trials that test whether products work and are safe, an agency official said Wednesday. Those guidelines are five months late.

To ensure that drugs work for everyone, they must be tested on a representative sample of people. But researchers have found that many clinical trials exclude the people of color who are often most affected by the diseases that drugs treat.

To help fix that problem, Congress passed a law requiring companies to give the FDA their plans for diversifying clinical trials. As part of that process, the agency was expected to issue guidance by the end of last year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： In search for therapies for solid tumors, companies turn to claudin

hotspot

WSS

ALS groups 'won't be played again' by the FDA, drug sponsors

EF3 tornado rips through North Carolina amid extreme weather nationwide

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

FogPharma raises $145 million in rare Series E round

7 more heat

Hospitals struggle to profit from CAR

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

focus

Anesthesiologist group: stop taking Ozempic before surgery

Scientists unlock the key to scar

Bright Health sells Medicare Advantage business to Molina

Medical device lobby: We're tired of waiting on Medicare coverage

23andMe had bad news about my health. I wish a person had delivered it

How to fix the rural physician shortage in the U.S.

Duchenne breakthrough therapy leaves behind pioneering families

Change Healthcare cyberattack outage could last weeks

Novavax promises a turnaround & Lilly roils the obesity market

Why getting cancer drugs just got harder for rural patients

Wikipedia

Covid isolation guidance eased by the CDC

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Why getting cancer drugs just got harder for rural patients

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Mass General totes up its waste in a move to tackle climate change

AstraZeneca loses challenge to Medicare drug price negotiation

focus

focus

hotspot

hotspot